NCT02027116View on ClinicalTrials.gov

Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2017

Conditions
Hepatitis C, Chronic
Interventions
BIOLOGICAL

VGX-6150

Plasmid DNA delivered via IM injection with electroporation

Trial Locations (2)

Unknown

Pusan National University Hospital, Pusan

Yonsei University Severance Hospital, Seoul

Sponsors

Collaborators (1)

Inovio Pharmaceuticals
All Listed Sponsors
collaborator

Inovio Pharmaceuticals

INDUSTRY

lead

GeneOne Life Science, Inc.

INDUSTRY

NCT02027116 - Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection | Biotech Hunter | Biotech Hunter